SynthesisDiabetes & metabolic syndrome
Association of calcium channel blocker use with clinical outcome of COVID-19: A meta-analysis.
Synthesis in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Mapping cellular signaling pathways involved in SARS-CoV-2 spike protein-mediated syncytia formation.Infectious diseases & immunity · 2026Article
- From Parts to Whole: A Systems Biology Approach to Decoding Milk Fever.Veterinary sciences · 2025Review
- Impact of the COVID-19 pandemic on initiation of antihypertensive drugs in Sweden: an interrupted time series study.BMJ open · 2024Article
- Focus on the role of calcium signaling in ferroptosis: a potential therapeutic strategy for sepsis-induced acute lung injury.Frontiers in medicine · 2024Review
- Evolution of Cardiovascular Risk Factors in Post-COVID Patients.Journal of clinical medicine · 2023Article
- SARS-CoV-2 spike protein receptor-binding domain perturbates intracellular calcium homeostasis and impairs pulmonary vascular endothelial cells.Signal transduction and targeted therapy · 2023Article
- Links between COVID-19 and Parkinson's disease/Alzheimer's disease: reciprocal impacts, medical care strategies and underlying mechanisms.Translational neurodegeneration · 2023Review
- UK biobank: Enhanced assessment of the epidemiology and long-term impact of coronavirus disease-2019.Cambridge prisms. Precision medicine · 2023Review
- Eco-friendly spectrophotometric evaluation of triple-combination therapies in the treatment strategy of patients suffering from hypertension during coronavirus pandemic - Spectralprint recognition study.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy · 2022Article
- Effects of nutrients on immunomodulation in patients with severe COVID-19: Current knowledge.World journal of critical care medicine · 2022Review
- Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Hypertension and COVID-19: Updates from the era of vaccines and variants.Journal of clinical & translational endocrinology · 2022Article
- The calcium-sensing receptor in inflammation: Recent updates.Frontiers in physiology · 2022Review
- COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis.F1000Research · 2022Review
- Management of hypertension in patients with COVID-19: Implication of angiotensin-converting enzyme 2.Cardiology plus · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis meta-analysis aims to analyze the association of calcium channel blocker (CCB) use with COVID-19 clinical outcomes.
methodsPubMed, ProQuest, Science Direct, Scopus, and medRxiv databases were searched systematically in a limited period. The primary outcome was mortality.
resultsA total of 119,298 patients from 31 eligible studies were included. Pooled analysis of the random-effect model revealed CCB was not associated with reduced mortality (OR = 1.21 [95%CI: 0.98-1.49], p = 0.08). Interestingly, subgroup analysis in hypertensive patients revealed significantly reduced mortality (OR = 0.69 [95%CI: 0.52-0.91], p = 0.009).
conclusionCCB usage was not associated with the outcome of COVID-19. However, CCB was associated with a decreased mortality rate in hypertensive COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.